Boston Scientific Co. (NYSE:BSX) Holdings Boosted by Welch Group LLC

Welch Group LLC grew its holdings in Boston Scientific Co. (NYSE:BSX) by 70.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,539 shares of the medical equipment provider’s stock after purchasing an additional 1,882 shares during the period. Welch Group LLC’s holdings in Boston Scientific were worth $407,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brown Lisle Cummings Inc. grew its stake in Boston Scientific by 1.1% during the 4th quarter. Brown Lisle Cummings Inc. now owns 74,525 shares of the medical equipment provider’s stock valued at $6,657,000 after acquiring an additional 833 shares in the last quarter. Longboard Asset Management LP purchased a new stake in Boston Scientific in the 4th quarter worth approximately $298,000. Calamos Wealth Management LLC lifted its position in Boston Scientific by 0.6% in the 4th quarter. Calamos Wealth Management LLC now owns 155,432 shares of the medical equipment provider’s stock worth $13,883,000 after buying an additional 872 shares in the last quarter. Childress Capital Advisors LLC grew its holdings in shares of Boston Scientific by 6.0% during the 4th quarter. Childress Capital Advisors LLC now owns 6,201 shares of the medical equipment provider’s stock valued at $554,000 after acquiring an additional 350 shares in the last quarter. Finally, GEN Financial Management INC. acquired a new position in shares of Boston Scientific in the fourth quarter worth $266,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.7 %

Shares of NYSE BSX opened at $103.11 on Tuesday. Boston Scientific Co. has a 52-week low of $64.08 and a 52-week high of $104.25. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The business has a fifty day moving average of $93.47 and a two-hundred day moving average of $86.33. The stock has a market cap of $151.97 billion, a PE ratio of 85.22, a PEG ratio of 2.68 and a beta of 0.80.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company’s stock, valued at $87,306.06. This represents a 93.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 in the last ninety days. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. BTIG Research boosted their price target on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Truist Financial raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Bank of America increased their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Wells Fargo & Company boosted their price target on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Citigroup boosted their target price on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $100.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.